‘Tragedy in the making’: Top healthcare exec on why insurance will spike to subsidize a tax cut to millionaires and billionaires

John Driscoll, chairman of UConn Health and former Walgreens Boots Alliance president, warned that the scheduled expiration of enhanced Affordable Care Act premium tax credits (extended through 2025) would be “a tragedy in the making,” citing CBO estimates that premiums would rise for roughly 24 million marketplace enrollees and about 2 million people could lose coverage, while KFF projects a roughly 114% jump in average subsidized premium payments in 2026 and 50–64‑year‑olds could see increases of 75% or more (subsidized premiums had averaged under about $900 a year). He argues the policy cliff — coupled with Medicaid cuts, work requirements and tax changes in the One Big Beautiful Bill — will shift costs onto households and employers as hospitals and insurers raise prices to cover anticipated uncompensated care. Driscoll says political dysfunction has frozen meaningful ACA reform, warns Republicans risk backlash for undermining affordability, and urges pragmatic fixes such as drug‑price negotiation, immigration relief to shore up primary care, site‑neutral payment and broader value‑based/bundled payments (he disclosed he advises Connecticut Governor Ned Lamont).

Analysis

John Driscoll, chairman of UConn Health and former Walgreens Boots Alliance president, warned that the scheduled expiration of enhanced ACA premium tax credits (extended through 2025) would be “a tragedy in the making,” citing CBO estimates that premiums would rise for roughly 24 million marketplace enrollees and about 2 million people could lose coverage. KFF projects a roughly 114% increase in average subsidized premium payments in 2026 and notes adults ages 50–64 could face average premium hikes of 75% or more; enhanced credits had kept average subsidized premiums under about $900 a year.

Driscoll argues the subsidy cliff, combined with Medicaid cuts, work requirements and tax changes in the One Big Beautiful Bill, will shift costs from government to households and employers and drive hospitals and insurers to raise prices to anticipate uncompensated care. That dynamic implies higher healthcare inflation risk, enrollment declines in the marketplaces and concentrated exposure for older and rural populations, all of which could pressure payer and provider revenues and margins.

He frames the problem as political dysfunction that blocks pragmatic reform and recommends policy steps including expanded drug‑price negotiation, immigration reforms to relieve primary‑care shortages, site‑neutral payments and broader value‑based/bundled payment models. These proposed changes create a near‑term legislative catalyst and medium‑term structural risks and opportunities for payers, providers, pharma and primary‑care delivery models; Driscoll discloses his advisory role to Connecticut Governor Ned Lamont.

Key Decisions for Investors

• Monitor Congressional action and CBO/KFF updates on subsidy extension or lapse as the primary market catalyst and be prepared to adjust positions ahead of the expected 2026 premium shock
• Trim or hedge exposure to insurers and hospital operators with high marketplace, rural or older‑patient concentration because anticipated uncompensated care and price pass‑through could compress margins
• Assess pharma and supply‑chain exposure to expanded drug‑price negotiation risk and favor companies with durable pricing power or protected product portfolios
• Review WBA and retail/primary‑care plays for shifts in patient demand and reimbursement risk, and watch payer enrollment and medical‑loss‑ratio metrics for early signs of stress
• Maintain liquidity and prioritize names with strong balance sheets and predictable cash flows until policy clarity on subsidies and related reforms emerges